Anya Schiess is a General Partner at Healthy Ventures. Her favorite part of investing is working with entrepreneurs to market-proof ideas, identify early customers, and solve problems during the inevitable pivots along the way. 

Prior to co-founding Healthy Ventures, Anya led strategy and business development for Cardinal Health's medical services, distribution, and laboratory businesses. Spending most of her time on tech-enabled healthcare services, Anya became convinced that now was the right time to invest in early stage opportunities at the intersection of health and information technology. The convergence of consumerism, changing care delivery models, and digitization is creating the perfect storm for disruption. This generation's winners are being created now.

Prior to Cardinal Health, Anya was a venture capitalist at Thomas, McNerney & Partners, where she focused on life sciences, mostly in later-stage opportunities. She invested and was a board director or observer in: Virdante Pharma (acquired by Momenta Pharma, Invitae Corp (NYSE: NVTA), Celator Pharma (NASDAQ: CPXX), and Innopharma Inc (acquired by Pfizer Inc). At Thomas, McNerney, Anya saw and participated in the emerging 'digital health’ sector, initially investing in the rise of the genomics services subsector.

Before entering the investing arena, Anya held several sales and marketing leadership roles at Medtronic across the globe and worked with terrific teams to launch neurological, cardiovascular, and cardiac rhythm products. Prior experiences similarly centered around healthcare: implementing HIV/AIDS programs and negotiating contracts with large Asian factories for The Clinton Foundation, consulting with McKinsey as a member of the Pharmaceutical & Medical Products and Corporate Finance & Strategy practices, and working as part of the Piper Jaffray biotechnology equity research team. Prior to it all, she joined a seed-stage startup developing “smart” braces to help patients recover faster following orthopedic surgery.
 
Anya earned a BA cum laude from Princeton University and an MBA with honors from The Wharton School at the University of Pennsylvania.

Fund's investment verticals: digital health technology.